contributor Larry "Smith on Stocks" Smith has written six articles on
in the past 10 months, all of which have promoted the blockbuster potential of the company's cancer immunotherapy. Smith is long Northwest Biotherapeutics. In the same time period, I wrote a single column
expressing an opinion that investors should avoid Northwest Bio
, mainly because the company exaggerates and misleads investors about the data backing its cancer therapy. I have no financial interest in Northwest Bio.
In his latest article, Smith
accuses me of being unfair to Northwest Bio
. He believes his prodigious output on the stock represents "a balanced perspective."
Smith writes, "Mr. Feuerstein implies elsewhere in his blog that Northwest was attempting to portray this as a randomized trial comparing DCVax-L to a control group of patients and that this was deceitful." [DCVax is the name given to Northwest Bio's cancer therapy targeted at glioblastoma (GBM), a form of brain tumor.]
That's incorrect. What I said quite clearly was Northwest Bio was misleading investors by comparing overall survival data from its small-single arm study of DCVax in 20 GBM patients with survival data obtained from a separate group of 119 GBM patients who were not participants in Northwest Bio clinical trials.
Why is comparing sets of data from two different groups of patients misleading? I'll let Smith explain. Here's what he wrote about the phase I trials of DCVax in an
April 26, 2012 Seeking Alpha article
It's the only sensible thing he's ever written about the company and its lead drug:
The Phase I trials of DCVax-L enrolled a small number of patients in non-randomized trials performed at one clinical site. Such trials are subject to investigator bias, albeit inadvertent, as investigators have a tendency to select for younger, healthier patients. They are reluctant to enroll older, sicker patients with poor prognosis who might die regardless of treatment. No one wants to see a new drug be judged ineffective because it is given to patients for whom there is very little hope for survival. In Phase II and III clinical trials, however, such patients do find their way in. There is an axiom in cancer drug development that Phase III results are never as good as Phase II results and Phase II results are never as good as Phase I results. Comparing results from different trials is also viewed suspiciously because protocols and the characteristics of the patient populations can vary widely, especially when comparing small Phase I to large Phase III trials.
Smith offers good advice then immediately ignores it. The claims made by Northwest Bio about the DCVax survival data from a tiny number of patients should be met with extreme skepticism and distrust by investors. Instead, Smith accepts them unconditionally -- a classic and common mistake made by retail biotech investors. Institutional investors are wiser and more skeptical, which is why Northwest Bio's institutional investor ownership is de minimus.
Smith writes, "NWBO [Northwest Bio] was not able to finance through the capital markets until very recently because of the weak financial position of the company and the skepticism of the investment community about immunotherapy... Ms. Powers, certain non-traditional investors and Cognate were the only sources of capital available."